ticlopidine has been researched along with Diabetes Mellitus, Type 1 in 16 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed an overall reduction in ischemic events with more intensive antiplatelet therapy with prasugrel than with clopidogrel but with more bleeding." | 5.13 | Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I ( Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD, 2008) |
| " An independent endpoint review committee adjudicated all reported major adverse cardiovascular events, stent thromboses, and target-vessel revascularizations." | 1.33 | Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. ( Berge, C; Deme, M; Gershlick, AH; Guagliumi, G; Guyon, P; Lotan, C; Schofer, J; Seth, A; Sousa, JE; Stoll, HP; Urban, P; Wijns, W, 2006) |
| "We present a case report of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) developing in a kidney/pancreas transplant recipient after the initiation of treatment with clopidogrel for symptomatic coronary artery disease." | 1.31 | Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient. ( Chinnakotla, S; Fidler, ME; Hammeke, MD; Leone, JP; Tarantolo, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ju, L | 1 |
| McFadyen, JD | 1 |
| Al-Daher, S | 1 |
| Alwis, I | 1 |
| Chen, Y | 1 |
| Tønnesen, LL | 1 |
| Maiocchi, S | 1 |
| Coulter, B | 1 |
| Calkin, AC | 1 |
| Felner, EI | 1 |
| Cohen, N | 1 |
| Yuan, Y | 1 |
| Schoenwaelder, SM | 1 |
| Cooper, ME | 1 |
| Zhu, C | 1 |
| Jackson, SP | 1 |
| Wiviott, SD | 1 |
| Braunwald, E | 1 |
| Angiolillo, DJ | 1 |
| Meisel, S | 1 |
| Dalby, AJ | 1 |
| Verheugt, FW | 1 |
| Goodman, SG | 1 |
| Corbalan, R | 1 |
| Purdy, DA | 1 |
| Murphy, SA | 1 |
| McCabe, CH | 1 |
| Antman, EM | 1 |
| Roffi, M | 1 |
| Eberli, FR | 1 |
| Raynaud, A | 1 |
| Novelli, L | 1 |
| Rovani, X | 1 |
| Carreres, T | 1 |
| Bourquelot, P | 1 |
| Hermelin, A | 1 |
| Angel, C | 1 |
| Beyssen, B | 1 |
| Kremneva, LV | 1 |
| Shalaev, SV | 1 |
| Serebruany, VL | 1 |
| Dinicolantonio, JJ | 1 |
| Can, MM | 1 |
| Goto, S | 1 |
| Mann, T | 1 |
| Cubeddu, RJ | 1 |
| Raynor, L | 1 |
| Bowen, J | 1 |
| Schneider, JE | 1 |
| Rose, G | 1 |
| Cubeddu, G | 1 |
| Raza, JA | 1 |
| Jobe, RL | 1 |
| Newman, W | 1 |
| Zellinger, M | 1 |
| Brogan, GX | 1 |
| Peterson, ED | 1 |
| Mulgund, J | 1 |
| Bhatt, DL | 1 |
| Ohman, EM | 1 |
| Gibler, WB | 1 |
| Pollack, CV | 1 |
| Farkouh, ME | 1 |
| Roe, MT | 1 |
| Urban, P | 1 |
| Gershlick, AH | 1 |
| Guagliumi, G | 1 |
| Guyon, P | 1 |
| Lotan, C | 1 |
| Schofer, J | 1 |
| Seth, A | 1 |
| Sousa, JE | 1 |
| Wijns, W | 1 |
| Berge, C | 1 |
| Deme, M | 1 |
| Stoll, HP | 1 |
| Scheen, AJ | 1 |
| Legrand, D | 1 |
| Gragnoli, G | 1 |
| Signorini, AM | 1 |
| Tanganelli, I | 1 |
| Rubtsova, AL | 1 |
| Ametov, AS | 1 |
| Strakhov, VV | 1 |
| Chinnakotla, S | 1 |
| Leone, JP | 1 |
| Fidler, ME | 1 |
| Hammeke, MD | 1 |
| Tarantolo, S | 1 |
| Velikov, VK | 2 |
| Saltykov, BB | 1 |
| Galkina, AK | 1 |
| Kabaeva, EV | 1 |
| Frolova, AI | 2 |
| Privalova, EV | 1 |
| Savina, TS | 1 |
| Zelenchuk, NM | 2 |
| Shubina, OI | 1 |
| Iarovaia, LD | 1 |
| Orlando, E | 1 |
| Cortelazzo, S | 1 |
| Nosari, I | 1 |
| Lepore, G | 1 |
| Pagani, G | 1 |
| de Gaetano, G | 1 |
| Barbui, T | 1 |
| Smolenskiĭ, VS | 1 |
| Bokarev, IN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients[NCT01261273] | 18,000 participants (Actual) | Observational | 2010-08-25 | Completed | |||
| BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI[NCT02870985] | Phase 3 | 440 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
2 reviews available for ticlopidine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia | 2009 |
[Acute coronary syndrome in patients with carbohydrate metabolic disturbances (a review)].
Topics: Acute Coronary Syndrome; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogr | 2009 |
3 trials available for ticlopidine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Me | 2008 |
Coronary stenting in stable patients: identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Clo | 2003 |
[The use of ticlid in diabetic retinopathy].
Topics: Adolescent; Adult; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Female; Humans; Insulin; Male; M | 1997 |
11 other studies available for ticlopidine and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Compression force sensing regulates integrin α
Topics: Adult; Animals; Aspirin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 1; Female; Humans; Ma | 2018 |
Radiocephalic fistula complicated by distal ischemia: treatment by ulnar artery dilatation.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Catheters, Indwelling; Clopidogrel; Diabete | 2010 |
Unclassified pleomorphic and spindle cell pulmonary neoplasm with brain metastases after prasugrel.
Topics: Aged; Aspirin; Brain Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Clopidogrel; Colonic | 2013 |
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Cardiac Catheterization; Clopidogrel; Co | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopidogrel; Comorbidity; Coronary Di | 2006 |
Aspirin and clopidogrel resistance in patients with diabetes mellitus.
Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D | 2006 |
[Effects of ticlopidine on the plasma levels of beta-thromboglobulin and thromboxane B2 in types 1 and 2 diabetics].
Topics: Beta-Globulins; beta-Thromboglobulin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; | 1984 |
Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient.
Topics: Adult; Clopidogrel; Coronary Disease; Cyclosporine; Diabetes Mellitus, Type 1; Diabetic Nephropathie | 2000 |
[The efficacy of the antiaggregants ticlid and diabeton in correcting chronic intravascular microcoagulation of the blood in diabetic patients].
Topics: Adolescent; Adult; Aged; Blood Coagulation Tests; Chronic Disease; Diabetes Mellitus, Type 1; Diabet | 1991 |
Inhibition of ticlopidine of platelet adhesion to human venous subendothelium in patients with diabetes.
Topics: Adult; Bleeding Time; Diabetes Mellitus; Diabetes Mellitus, Type 1; Endothelium, Vascular; Female; F | 1988 |
[Effect of ticlopidine on the course of diabetic microangiopathy].
Topics: Adult; Conjunctiva; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fema | 1988 |